Our EGFR-targeted nanomedicines with anti-EGFR scFv ligands (NM-scFv) were able to not only effectively protect and deliver siRNA into EGFR-overexpressing cancer cells but also can be tracked in vivo with single-photon emission computed tomography coupled with computed X-tomography (SPECT-CT) imaging. The gene discussed is EGFR; the disease is cancer.